



**SOLBEC
PHARMACEUTICALS LTD**

ASX RELEASE

27th November 2003

Jervois Mining Project

Summary:

- Solbec sells Jervois mining lease for \$1,000,000
- Terms of Sale are \$500,000 cash \$500,000 production royalties
- The sale marks the divesting of the last of Solbec's mineral assets.

Solbec Pharmaceuticals Ltd advises that it has agreed to the sale of its interests in the Jervois Copper Mining Project to Asia Multi-Foods and Oils (Australia) Ltd.

The terms of the sale, are \$500,000 cash and the balance as a royalty from production calculated at \$2 per tonne of ore mined capped at \$500,000 providing the company with a total of \$1,000,000 for the asset.

The sale agreement is in line with the company's policy of divesting its mineral assets and will contribute significantly to the company's cash reserves with an immediate cash injection of \$500,000. This sale marks the divesting of Solbec's last major mineral asset.

Stephen Carter
Managing Director
Tel: +61(08) 9446 7555
Fax: +61(08) 9446 8777
Email: stephen.carter@solbec.com.au

Background Information

Solbec Pharmaceuticals Ltd is a publicly listed company on the Australian Stock exchange (code SBP).

SBP002 is a combination of two glycoalkaloids isolated from the fruit of *Solanum linnaeanum*, a weed more commonly known as Devil's Apple.

Currently the drug has completed its pre-clinical phase of trials as an anti cancer treatment. Human Phase I clinical trials are now underway.

Solbec is focussing SBP002 research on treatment of mesothelioma and malignant melanoma which qualifies the drug for the fast track Orphan Drug Program.

However, under the Therapeutic Goods Administration's Special Access Scheme (SAS), SBP002 has been administered to a number of cancer patients with encouraging results. These have included: Increased well-being, Tumour size reduction, Reduced tumour growth rates, extended expected life span, Tumour eradication

In previous studies carried out by the University of Western Australia, it was observed that SBP002-treated cells reduced the production of IL-6 when compared to the control and to cells treated with the anti-cancer drugs Gemcitabine and Docetaxol. IL-6 is known to be one of the chemicals produced by the body during disease that makes people feel unwell. IL-6 is also known to be involved in cancer cell proliferation.

As well as a range of cancers, SBP002 may be useful for treating a wide range of IL-6 related diseases. These include inflammatory diseases such as rheumatoid arthritis; microbial diseases such as HIV, chronic fatigue syndrome and malaria; heart disease such as cardiac myopathy; and other diseases such as Alzheimer's disease, arteriosclerosis, thyroiditis and Castleman's disease. Solbec has lodged patents to cover this exciting aspect of the drug's activity.

Solbec has received an Australian Government grant of \$196,000 through the Ausindustry Biotechnology Innovation Fund to carry out further research on SBP002. This research is to look at the ability of SBP002 to boost the immune system. This new line of investigation at UWA by Professor Robinson and his team represents a significant new direction for Solbec and the use of SBP002.